RGNX REGENXBIO Inc.
8-K Current Report
Filed: March 5, 2026
Health Care
Biological Products, (No Diagnostic Substances)REGENXBIO Inc. (RGNX) 8-K current report filed with SEC EDGAR on March 5, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 2.02: Results of Operations and Financial Condition
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings release issued March 5, 2026
- • Detailed financial results in Exhibit 99.1 — key figures for revenue, cash, and pipeline updates found there
Get deeper insights on REGENXBIO Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.